DBV Technologies S.A. in brief
DBV Technologies S.A. is a listed company in the Biotechnology industry, based in France. It was founded in 2002. Its last known market value was $194 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $6 M and a net loss of $188 M. Its shares trade under the symbol DBV.PA (EURONEXT).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About DBV Technologies S.A.
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies S.A. timeline
- 2002
- 🏁· approximateFounded
- 2014
- 🔔· approximateInitial public offering on Nasdaq as DBVT
- 2017
- •Legal Entity Identifier issuedLEI 969500PVBQFWQKVDMD80 registered.
Events of DBV Technologies S.A. from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in France: #135 (Jan 2020) · #249 (Jan 2021) · #284 (Jan 2022) · #231 (Dec 2022) · #208 (Jul 2023) · #250 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -3337.1%
- Operating margin
- -2607.4%
- Return on equity
- -111.5%
- Liabilities / assets
- 27.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-147M | $-147M | — |
| Dec 2024 | — | — | $-116M | $-114M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-120M | — | — | $-1.05 | — |
| Dec 2024 | $-103M | — | — | $-1.18 | — |
Annual results
- Revenue
- $6 M
- Operating income
- $-147 M
- Net income
- $-188 M
For year ending December-2025
Balance sheet
- Total assets
- $234 M
- Total liabilities
- $65 M
- Total equity
- $169 M
As of December-2025
Mutual funds holding DBV Technologies S.A.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Core MSCI EAFE ETFBlackRock Fund Advisors | 653,086 | $2 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares MSCI EAFE Small-Cap ETFBlackRock Fund Advisors | 634,957 | $2 M | — | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 117,668 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 104,702 | $0 M | — | 0.04% | +18% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC | 108,080 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Core MSCI Europe ETFBlackRock Fund Advisors | 96,952 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity SAI International Small Cap Index FundFidelity Management & Research Company LLC | 51,082 | $0 M | — | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Core MSCI Total International Stock ETFBlackRock Fund Advisors | 40,838 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares MSCI Europe Small-Cap ETFBlackRock Fund Advisors | 19,925 | $0 M | — | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio Europe ETFSSGA Funds Management, Inc. | 8,318 | $0 M | — | <0.01% | +152% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
DBV Technologies S.A. scorecard#
Passes 0 of the 3 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.05 vs -1.18Diluted EPS -1.05 in fiscal 2025 against -1.18 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$147 MNet income -$147 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-150.0%-150.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
DBV Technologies S.A.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | 0—— | 0—— | 0—— | 0—— | |
| Research and development | 117+30.7%— | 89+48.3%— | 60−20.1%— | 75+7.3%— | 70−30.8%— | 101—— | |
| Total costs and expenses | 153+26.5%— | 121+31.1%— | 92−8.9%— | 101−2.8%— | 104−38.6%— | 169—— | |
| Operating income | −147—— | −116—— | −76—— | −96—— | −98—— | −158—— | |
| Interest and finance income | 2.8−28.2%— | 3.9−21.6%— | 5.0+631%— | 0.7+31.3%— | 0.5+114%— | 0.2—— | |
| Interest expense and finance costs | 2.6+70.1%— | 1.5+7.7%— | 1.4+226%— | 0.4−37.8%— | 0.7−65.0%— | 2.0—— | |
| Income tax | 0.5+793%— | 0.1+686%— | 0.0−90.0%— | 0.1—— | −0.4—— | −0.0—— | |
| Net income including minority interests | −147—— | −114—— | −73—— | −96—— | −98—— | −160—— | |
| Earnings per share, basic | -1.05—— | -1.18—— | -0.76—— | -1.24—— | — | — | |
| Earnings per share, diluted | -1.05—— | -1.18—— | -0.76—— | -1.24—— | — | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 194+498%83.2% | 32−77.0%49.5% | 141−32.4%77.3% | 209+171%84.9% | 77−60.6%52.8% | 196—72.2% | |
| Receivables | — | — | 0—0.0% | 0—0.0% | 0−100%0.0% | 2.2—0.8% | |
| Other current assets | — | — | 18+26.1%9.6% | 14−62.6%5.6% | 37+323%25.4% | 8.8—3.2% | |
| Current assets | 213+380%91.2% | 44−72.1%67.7% | 159−28.8%86.8% | 223+94.8%90.5% | 115−44.8%78.3% | 207—76.2% | |
| Property, plant and equipment | 10−8.3%4.4% | 11−10.4%17.3% | 13−16.4%6.9% | 15−16.8%6.1% | 18−26.8%12.4% | 25—9.1% | |
| Right-of-use (leased) assets | 4.3−20.7%1.8% | 5.4+2.4%8.2% | 5.3+114%2.9% | 2.5−63.7%1.0% | 6.8−31.4%4.6% | 9.9—3.6% | |
| Other intangible assets | 0.0−45.0%0.0% | 0.0−29.8%0.1% | 0.1+470%0.0% | 0.0−54.5%0.0% | 0.0−46.3%0.0% | 0.0—0.0% | |
| Non-current assets | 20−3.2%8.8% | 21−12.2%32.3% | 24+3.0%13.2% | 23−26.5%9.5% | 32−50.8%21.7% | 65—23.8% | |
| Total assets | 233+256%100% | 66−64.2%100% | 183−25.8%100% | 246+68.5%100% | 146−46.2%100% | 272—100% | |
| Accounts payable | — | — | — | — | 11−43.8%7.8% | 20—7.5% | |
| Debt due within a year | — | — | 0—0.0% | 0−100%0.0% | 0.5−29.6%0.3% | 0.7—0.3% | |
| Current liabilities | 58+86.4%24.9% | 31−16.6%47.5% | 37+26.5%20.4% | 30−6.0%12.0% | 31−40.4%21.5% | 53—19.4% | |
| Long-term debt | — | — | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.5—0.2% | |
| Lease liabilities (non-current) | 5.4−14.1%2.3% | 6.3+39.1%9.6% | 4.5+294%2.5% | 1.2−83.9%0.5% | 7.1−31.9%4.9% | 10—3.9% | |
| Non-current liabilities | 6.6−5.9%2.8% | 7.0+31.8%10.7% | 5.3−76.3%2.9% | 22+41.4%9.1% | 16+14.2%10.9% | 14—5.1% | |
| Shareholders' equity | 169+516%72.3% | 27−80.5%41.8% | 140−27.8%76.7% | 194+96.4%78.9% | 99−51.8%67.7% | 205—75.5% | |
| Total equity | 169+516%72.3% | 27—41.8% | — | — | — | — | |
| Total liabilities and equity | 233+256%100% | 66−64.2%100% | 183−25.8%100% | 246+68.5%100% | 146−46.2%100% | 272—100% | |
| Shares outstanding | 236+129%— | 103+6.7%— | 96+2.4%— | 94+70.9%— | 55+0.3%— | 55—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 5.4+16.6%— | 4.6−23.2%— | 6.0+19.8%— | 5.0+61.0%— | 3.1—— | −1.1—— | |
| Cash from operating activities | −120—— | −103—— | −78—— | −51—— | −104—— | −161—— | |
| Capital expenditure | — | — | −0.7—— | −0.8—— | −0.9—— | −2.8—— | |
| Intangible assets bought | — | — | 0—— | 0—— | −0.0—— | −0.0—— | |
| Cash from investing activities | −1.4—— | −0.8—— | −0.8—— | −0.1—— | −0.4—— | −2.9—— | |
| Debt issued | — | — | 0—— | 0—— | 0—— | 0—— | |
| Debt repaid | — | — | 0—— | −0.5—— | −0.7—— | −0.3—— | |
| Shares issued | — | — | 6.9−96.4%— | 194+24393%— | 0.8−99.5%— | 150—— | |
| Cash from financing activities | 275—— | −0.7−115%— | 4.8−97.5%— | 190—— | −3.9−103%— | 145—— | |
| Exchange-rate effect on cash | 8.1—— | −4.3−173%— | 5.9—— | −6.5—— | −11−148%— | 22—— | |
| Change in cash | — | — | — | — | −108—— | −19—— | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How DBV Technologies S.A. compares in Biotechnology
- Revenue$6 M · higher than 37% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| DBV Technologies S.A.🇫🇷 | $194 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 9, 2026
Figures from value.today research, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at DBV Technologies S.A.? Verify and update this profile — free
Show DBV Technologies S.A.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.